Axiom Biosciences Targets US$200M Hong Kong IPO in 2027, US Listing in 2029
Quick Look
- Axiom Biosciences, a US-based biotech firm developing AI-powered therapies for newborn brain injuries, is targeting a US$200 million initial public offering (IPO) in Hong Kong by 2027, with a secondary listing in the US planned for 2029.
- CEO Remo Moomiaie-Qajar highlighted Hong Kong's mature market for healthcare listings.
AI-generated summary
Why It Matters
Axiom Biosciences, founded in 2018 and headquartered in San Diego, develops experimental therapies for newborns with severe brain injuries using AI, having raised US$17.17 million over 13 funding rounds.
Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029.
“Some of the most important science in the world is being built in the United States, but the way it gets funded hasn’t kept pace,” said Remo Moomiaie-Qajar, founder and CEO of Axiom, in a statement.
In an interview, Moomiaie-Qajar said healthcare companies that listed in Hong Kong have been, for the last several years, outperforming Nasdaq listings during the same period. Hong Kong was “more mature and understanding of how to handle publicly listed companies” in the sector, he said.
The company said it would be the first biotech firm operating in the US to list in Hong Kong.
Founded in 2018 and headquartered in San Diego, California, Axiom had raised US$17.17 million over 13 funding rounds, according to CB Insights.
What to Watch
AI outlook — possibilities, not facts
Axiom Biosciences will pursue an IPO in Hong Kong by 2027.
Very likely · Within months
Axiom Biosciences will pursue a secondary listing in the US by 2029.
Very likely · Within months
Open Questions
- What specific therapies is Axiom developing?
- What is the current stage of Axiom's experimental therapies?
- What are the specific reasons for choosing Hong Kong first?
